Tubulis inks $415M ADC collaboration with Gilead Dec. 3, 2024 By Nuala Moran Tubulis GmbH has sealed a potential $415 million option and licensing deal under which it will apply proprietary technologies to discover an antibody-drug conjugate (ADC) against a solid tumor target for Gilead Sciences Inc.Read More
